262 related articles for article (PubMed ID: 35593358)
1. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond.
Soltani M; Savvateeva LV; Ganjalikhani-Hakemi M; Zamyatnin AA
Curr Drug Targets; 2022; 23(11):1072-1084. PubMed ID: 35593358
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Mougel A; Terme M; Tanchot C
Front Immunol; 2019; 10():467. PubMed ID: 30923527
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.
Zhao J; Chen Y; Ding ZY; Liu JY
Front Pharmacol; 2019; 10():1184. PubMed ID: 31680963
[TBL] [Abstract][Full Text] [Related]
4. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines.
Oladejo M; Paulishak W; Wood L
Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110
[TBL] [Abstract][Full Text] [Related]
5. [Cancer Vaccine Focused on Neoantigens].
Shindo Y; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2019 Sep; 46(9):1367-1371. PubMed ID: 31530772
[TBL] [Abstract][Full Text] [Related]
6. Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors.
Strauss J; Madan RA; Gulley JL
Expert Opin Biol Ther; 2016 Jul; 16(7):895-901. PubMed ID: 27010190
[TBL] [Abstract][Full Text] [Related]
7. Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy.
Collins JM; Redman JM; Gulley JL
Expert Rev Vaccines; 2018 Aug; 17(8):697-705. PubMed ID: 30058393
[TBL] [Abstract][Full Text] [Related]
8. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
9. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
[TBL] [Abstract][Full Text] [Related]
10. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
Ni K; Luo T; Nash GT; Lin W
Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
[TBL] [Abstract][Full Text] [Related]
11. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
Wang QT; Liu YX; Wang J; Wang H
ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
[TBL] [Abstract][Full Text] [Related]
12. [Tumor Immunogenicity and Immune Checkpoint Inhibitors].
Nakajima M; Tsunedomi R; Shindo Y; Tokumitsu Y; Matsui H; Watanabe Y; Tomochika S; Yoshida S; Iida M; Suzuki N; Takeda S; Ioka T; Hazama S; Nagano H
Gan To Kagaku Ryoho; 2022 Sep; 49(9):922-927. PubMed ID: 36156006
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.
Liao JY; Zhang S
Front Oncol; 2021; 11():663264. PubMed ID: 34123821
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment antigens.
Andersen MH
Semin Immunopathol; 2023 Mar; 45(2):253-264. PubMed ID: 36175673
[TBL] [Abstract][Full Text] [Related]
15. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
16. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
17. Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.
Zhao P; Xu Y; Ji W; Li L; Qiu L; Zhou S; Qian Z; Zhang H
Int J Nanomedicine; 2022; 17():73-89. PubMed ID: 35027827
[TBL] [Abstract][Full Text] [Related]
18. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
[TBL] [Abstract][Full Text] [Related]
19. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
20. Current progress in immunotherapy for pancreatic cancer.
Foley K; Kim V; Jaffee E; Zheng L
Cancer Lett; 2016 Oct; 381(1):244-51. PubMed ID: 26723878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
